The startup develops injectable bio-structural gel implants that are administered into the nucleus of intervertebral discs to restore mechanical function and alleviate back pain. This micro-invasive procedure, completed in under 30 minutes, creates a supportive scaffold that suppresses degenerative processes in spinal discs.
Funding
$15.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic low back pain, often caused by degenerative disc disease (DDD), is a leading cause of disability worldwide. Degeneration begins with disc dehydration, leading to height loss and altered spinal mechanics, which in turn increases inflammatory markers and pain. Current treatments often mask pain without addressing the underlying mechanical and cellular causes of degeneration.
Solution
OrthoSon develops bio-structural gel implants designed to restore the intervertebral disc and alleviate back pain by addressing both the mechanical and cellular sources of pain and degeneration. The low-viscosity, injectable gel is administered in a micro-invasive procedure, taking less than 30 minutes, and flows into the fissures of degeneration within the disc. Once in place, the gel forms a mechano-biological structure that mimics the body’s own tissue, restoring tension in the annulus and mechanical function of the intervertebral disc. This creates a supportive scaffold that suppresses degenerative processes and promotes a healthier disc environment.
Target Audience
The primary target audience includes spine specialists and interventional pain physicians treating patients with discogenic low back pain, as well as hospitals and clinics specializing in orthopedic and pain management solutions.
Features
- Injectable, in-situ forming bio-structural gel
- Low-viscosity formulation that flows into fissures within the degenerated disc
- Patented polymer designed to mimic the nucleus pulposus, with 82% water content and healthy osmolarity
- Restores disc height and mechanical function
- Suppresses factors driving disc degeneration
- Micro-invasive, single-procedure treatment with short recovery time
- Does not accelerate degeneration, suitable for earlier intervention
- FDA Breakthrough Device designation